News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Orion Pharma’s Mixed Results; Abbott Laboratories Shares Drop After Study Of Simdax Disappoints
November 15, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Nov. 15 (Bloomberg) -- Shares of Orion Oyj, the Nordic region's third-largest drugmaker, dropped as much as 14 percent after researchers said the Simdax heart failure treatment caused some complications and didn't lower death rates.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Abbott Laboratories
MORE ON THIS TOPIC
Diabetes
Lilly Tops Novo in Weight Loss Again, This Time on the Oral Front
February 26, 2026
·
2 min read
·
Annalee Armstrong
HIV
Gilead, Merck Clear Path to Market for Daily HIV Pills With New Late-Stage Data
February 26, 2026
·
2 min read
·
Tristan Manalac
Regulatory
Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study
February 25, 2026
·
2 min read
·
Tristan Manalac
Podcast
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
February 25, 2026
·
2 min read
·
Heather McKenzie